These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 11436110

  • 1. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F, Sanz GF, de La Rubia J, Jiménez C, Saavedra S, Regadera A, Andreu R, García I, Plumé G, Martínez J, Martín G, Jarque I, Sanz MA.
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [Abstract] [Full Text] [Related]

  • 3. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [Abstract] [Full Text] [Related]

  • 4. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
    Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC.
    Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
    [Abstract] [Full Text] [Related]

  • 5. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D.
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [Abstract] [Full Text] [Related]

  • 6. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L, Destro R, Gazzola MV, Varotto S, Errigo G, Carli M, Zanesco L, Messina C.
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [Abstract] [Full Text] [Related]

  • 7. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.
    Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M.
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1713-20. PubMed ID: 21708110
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
    Nivison-Smith I, Bradstock KF, Szer J, Durrant S, Dodds A, Hermann R, Schwarer AP, Gibson J, To LB, Arthur C, Australian Bone Marrow Transplant Cooperative Sutdy Group.
    Bone Marrow Transplant; 2001 Jul; 28(1):21-7. PubMed ID: 11498740
    [Abstract] [Full Text] [Related]

  • 9. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, Hiruma K, Matsunaga T, Morita T, Sakamaki H.
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [Abstract] [Full Text] [Related]

  • 10. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [Abstract] [Full Text] [Related]

  • 11. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M, Wegner H, Goehring P, Salat C, Pihusch V, Andreesen R, Kolb HJ, Holler E, Pihusch R.
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [Abstract] [Full Text] [Related]

  • 12. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.
    Klin Padiatr; 2005 Oct; 217(3):135-41. PubMed ID: 15858704
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M, Mattsson J, Hassan Z, Karlsson N, LeBlanc K, Omazic B, Okas M, Sairafi D, Ringdén O.
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [Abstract] [Full Text] [Related]

  • 14. Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation.
    Najima Y, Ohashi K, Miyazawa M, Nakano M, Kobayashi T, Yamashita T, Akiyama H, Sakamaki H.
    Am J Hematol; 2009 May; 84(5):298-301. PubMed ID: 19338041
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood.
    Kato S, Yabe H, Yasui M, Kawa K, Yoshida T, Watanabe A, Osugi Y, Horibe K, Kodera Y.
    Bone Marrow Transplant; 2000 Dec; 26(12):1281-90. PubMed ID: 11223967
    [Abstract] [Full Text] [Related]

  • 16. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
    Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J, Caballero MD, de Oteyza JP, Zuazu J, Moraleda JM, Ojeda E, Ferrá C, Serrano D, De La Cámara R, Urbano-Ispízua A, Brunet S, AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Español de Trasplante Hematopoyético (GETH).
    Haematologica; 2001 Oct; 86(10):1075-86. PubMed ID: 11602414
    [Abstract] [Full Text] [Related]

  • 17. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
    Horn B, Reiss U, Matthay K, McMillan A, Cowan M.
    Bone Marrow Transplant; 2002 Mar; 29(5):409-15. PubMed ID: 11919731
    [Abstract] [Full Text] [Related]

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, Carson E, Eisbruch A, Dawson LA, McDonagh K, Ferrara J, Uberti J.
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC.
    Bone Marrow Transplant; 2007 Nov; 40(10):935-44. PubMed ID: 17768390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.